Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lymphoma

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation

Abstract

Although anaplastic large-cell lymphomas (ALCL) carrying anaplastic lymphoma kinase (ALK) have a relatively good prognosis, aggressive forms exist. We have identified a novel translocation, causing the fusion of the TRAF1 and ALK genes, in one patient who presented with a leukemic ALK+ ALCL (ALCL-11). To uncover the mechanisms leading to high-grade ALCL, we developed a human patient-derived tumorgraft (hPDT) line. Molecular characterization of primary and PDT cells demonstrated the activation of ALK and nuclear factor kB (NFkB) pathways. Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expansion of lymphoma cells, lacking PRDM1/Blimp1 and carrying c-MYC gene amplification. The treatment with proteasome inhibitors of TRAF1-ALK cells led to the downregulation of p50/p52 and lymphoma growth inhibition. Moreover, a NFkB gene set classifier stratified ALCL in distinct subsets with different clinical outcome. Although a selective ALK inhibitor (CEP28122) resulted in a significant clinical response of hPDT mice, nevertheless the disease could not be eradicated. These data indicate that the activation of NFkB signaling contributes to the neoplastic phenotype of TRAF1-ALK ALCL. ALCL hPDTs are invaluable tools to validate the role of druggable molecules, predict therapeutic responses and implement patient specific therapies.

Introduction

Anaplastic large-cell lymphomas (ALCL) are a distinct subset of mature T-cell lymphomas and they can be subclassified based on the presence of chromosomal translocations affecting the anaplastic lymphoma kinase (ALK) gene.1, 2 In the 2008 revised WHO classification, ALK+ ALCL and cutaneous ALCL received distinct designations, whereas ALK− ALCL remained as a provisional entity in the anticipation of additional data.2

De novo ALK+ ALCL are clinically aggressive lymphomas, most frequently occurring in the first three decades of life, with a stage III–IV disease, systemic symptoms, extranodal involvement (60%) and a typical male predominance.3, 4 Although the long-term clinical outcome for the majority of ALK+ ALCL patients is relatively favorable,3, 4 some patients can have a highly aggressive disease. Clinical development can include rapid nodal dissemination, extranodal involvement or even frank leukemic presentation.5, 6 Moreover, 20–30% of ALK+ ALCL patients relapse and eventually require high-dose chemotherapies and bone marrow transplantation.3, 4, 7

The majority of ALK+ ALCL cases carry the t(2;5)(p23;q35) translocation, which fuses the 3′ portion of the ALK into the nucleophosmin (NPM) gene. As a result of this translocation, affected cells display ectopic expression of the NPM-ALK fusion protein within the cytoplasm and nucleus. Approximately 20% of cases of ALK+ ALCL, however, exhibit different ALK fusions with a cytoplasmic localization.8 The N-terminus regions of all ALK chimera encode unique dimerization domains. These are critical for the constitutive activation of the kinases and required for ALK-mediated transformation. It is believed that ALK partners do not contribute otherwise to ALK lymphomagenesis. One notable exception has been identified in the TFG-ALK fusion, in which the TFG (TRK-fused gene) region can interact with IKBKG (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma, NEMO) and TANK (TRAF family member-associated NFKB activator) leading to the nuclear factor kB (NFkB) activation.9

ALK+ ALCL have often a stable karyotype,10 supporting the hypothesis that they are highly addicted to ALK signaling and may not require multiple and synergizing alterations. Conversely, aggressive ALK+ cases have a large spectrum of chromosomal defects, frequently involving chromosome 8q, suggesting that the deregulated expression of MYC might lead to unfavorable clinical outcome.5, 6, 11, 12

Patient-derived tumorgrafts (PDTs) in heavily immunocompromised animals (that are, NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice) are a valuable instrument to study human cancers.13 These mice display a high rate of engraftment14 and provide a host environment capable to sustain the survival of neoplastic as well as normal human elements.13 The expansion of primary tumor cells provides abundant pathological tissues and the opportunity to test ad hoc protocols in a reasonable time-frame.15 At last, PDT enables the discovery of genetic lesions, which can be targeted by specific compounds16 in preclinical therapeutic protocols.17, 18, 19

Here, we have studied the tumorigenic properties of a novel TRAF1-ALK chimera,20, 21 which can elicit the inappropriate activation of ALK and NFkB pathways. Additional, multiple genomic defects (loss of TP53, PRDM1 and MYC amplification) were present in a leukemic and chemoresistant TRAF1-ALK ALCL patient. Notably, the usage of a specific ALK inhibitor was able to prolong the survival of ALCL PDTs, but not to eradicate the disease. Overall, PDT models represent a novel tool to validate therapeutic protocols and to predict clinical responses, particularly in the setting of refractory patients.

Materials and methods

Patients selection and immunohistochemistry

Fresh and/or viable cryopreserved samples from primary ALCL were obtained at the time of diagnosis, before treatment or at relapse after chemotherapy from the Universities of Perugia, Turin and Leuven. Diagnoses were made according to the WHO classification by at least two experienced pathologists. Informed consents were obtained following the recommendations of local ethical committees. Representative formalin-fixed tumor sections and/or tissue microarrays were processed for immunohistochemical analyses on a semi-automated stainer.22 List of the antibodies and staining conditions are provided in Supplementary Table S1.

Fluorescence in situ hybridization analysis

Cytogenetic and fluorescence in situ hybridization (FISH) followed routine methods. Interphase FISH was performed on formalin-fixed, paraffin-embedded sections. Formalin-fixed, paraffin-embedded sections were pretreated with SPOT-Light Tissue Pretreatment Kit (Life Techologies), following manufacturer’s protocol. Probes applied for FISH included LSI ALK, LSI MYC, LSI TP53/CEP17 (Abbott Molecular, Ottigne, Belgium or Rome, Italy) and home-brewed bacterial artificial chromosome clones flanking TRAF1 or BRCA1 genes (Supplementary Table S2), selected from www.ensembl.org, or PRDM1 gene, kindly provided by Dr Laura Pasqualucci (Columbia University, New York, NY, USA). Non-commercial probes were labeled with SpectrumOrange- and SpectrumGreen-d-UTP (Abbott Molecular) using random priming. FISH images were acquired with a fluorescence microscope equipped with an Axiophot 2 camera (Carl Zeiss Microscopy, Jena, Germany) and a MetaSystems ISIS imaging system (MetaSystems, Altlussheim, Germany). Approximately 100 interphase cells were evaluated in each analysis.

RNA-Seq library preparation and bioinformatics analysis

RNAseq was performed as previously described23 (Supplementary Information). Bionformatics analyses were accomplished using dedicated fusion detection tools (Bellerophontes,24 Defuse,25 ChimeraScan26 and TxFuse27).

5′ Race and RT-qPCR

Race28 and real-time quantitative polymerase chain reaction (RT-qPCR)29 were performed as described. The PCR cycling conditions were: 95 °C for 5 min, followed by 40 cycles at 94 °C for 10 s and 60 or 62 °C for 30 s. Primer sequences are available if requested.

Mice and mice treatment

NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice were bred within the Molecular Biotechnology Center Animal Resource, under strict specific and opportunistic pathogen-free conditions. Animal protocols were reviewed and approved by the Animal Committee of the University of Turin. CEP28122 (Cephalon, 100 mg/kg body weight BID) were administered by oral gavage. Magnetic resonance imaging and data analysis and post-processing are described in the Supplementary Information.

Tumor grafting and harvesting

Leukemic ALCL cells were obtained from a peripheral blood sample of a refractory ALK+ ALCL patient (Supplementary Table S1). For the initial tumorgraft implants, lymphoma cells (10–12.5 × 106, 200 μl of Dulbecco’s phosphate-buffered saline) were injected intravenously (i.v., tail vein), intraperitoneally (i.p.) or subcutaneously (s.c.) in a total of 5–8-week-old anaesthetized NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice (Rompun 0.05 μl/g e Zoletil 1.6 μg/g intramuscularly). Secondary transplants were performed by injecting 1 × 106 ALCL cells i.v. or alternatively implanting s.c. tumor lymphoma fragments (2–4, 3 × 3 × 1 mm fragments).30 Implants’ growth was assessed either by palpation (s.c) and by magnetic resonance imaging. Presence and immunophenotype of human blood-circulating cells were determined by multicolor flow cytometry.31 Recipient animals were checked regularly and killed at early signs of distress. At harvesting, mice were killed in a CO2 chamber and tissue grafts were collected for histologic evaluation, re-grafting, cryopreservation or snap-freezing in liquid nitrogen.

The log-rank (Mentel–Cox) test was used to compare survival rates among different populations. The cumulative probability of overall survival was plotted as a curve according to the Kaplan–Meier method.

Antibodies western blotting and immune-precipitation assays

The following primary antibodies were used for western blotting: anti-ALK (Life Technology, Monza, Italy; mouse 1:2000), TRAF1 (Santa Cruz, rabbit 1:1000) and TRAF2 (Santa Cruz, Heidelberg, Germany; mouse 1:1000) anti-Actin Millipore (Merk-Millipore, Milano, Italy; mouse 1:2000), and anti-MYC (rabbit 1:1000), antiphospho-STAT3 (rabbit 1:1000), anti STAT3-Y705 (rabbit 1:1000), anti SHP2 (rabbit 1:1000), anti SHP2-Y542 (rabbit 1:1000), anti ERK1/2-Thr202/Tyr204 (rabbit 1:1000), p50 NFkB (rabbit 1:1000) and p52 NFkB (rabbit 1:1000) from Cell Signaling Technology (Danvers, MA, USA). Western blotting and immunoiprecipaitation studies were performed as previously described.32, 33, 34

Cell cultures and viability

Human ALCL cells (TS-SUP-M2, JB-6, Karpass 299, L82 and SU-DHL-1) were cultured under standard conditions (37 °C in humidified atmosphere, with 5% CO2) in RPMI 1640 (Sigma-Aldrich, St Luis, MO, USA) and supplemented with 10% fetal calf serum (Lonza, Rockland, ME, USA), 2 mM ghlutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Eurobio Biotechnology, Les Ulis, France). Human embryonal kidney cells HEK293T (ATCC, Manassas, VA, USA) were cultivated in supplemented Dulbecco modified Eagle medium. Cell viability was measured by ATP-lite using PerkinElmer luminometer. Bortezomib, Tripolide and Carfilzomib (Selleck, Houston, TX, USA), CEP28122 (Teva, West Chester, PA, USA) and Crizotinib (Chemitek, Indianapolis, IN, USA) were used for in vitro or in vivo studies.

ΔTRAF1-ALK (ΔT/A) and ΔNPM-ALK cassettes were constructed by PCR including the first 299 aa of TRAF1 and 100aa of NPM link to a short peptide corresponding to the intracytoplasmic region of the ALK gene (first 21 aa of the juxta-membrane region). Transfection of HEK293T cells was performed with Effectene reagent (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions.

Luciferase analysis

Cells were transfected with multiple plasmids in association with pGL3 SOCS3 or IgK–HIV-kB-driven luciferase reporter and Renilla (1–40 ratio) constructs to test the TRAF1-ALK NFkB-mediated transcriptional activity. After transfection (36 h), cell lysates were prepared from 4 × 104 cells and dispensed in 96-well plate following the manufacturers instructions. Luciferase expression levels were determined following the recommended protocol (Dual-Luciferase Reporter Assay, Promega, Milano, Italy).

Gene expression profiling, processing and data analysis of microarray data

A gene expression profiling (GEP) data set29 was analyzed as previously described.29, 35 The neoplastic profiles were derived from ALCL (ALK−, no.=24; ALK+, no.=30), peripheral T-cell lymphoma not otherwise specified (no.=74) and angioimmunoblastic T-cell lymphoma (AITL, no.=41). For the extension/validation analysis, we used the total of de novo 59 ALCL samples (46 clinically annotated) of the Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project.36 Hierarchical clustering and dendrogram were generated with the GenePattern2.037 suite (Pearson correlation distance measure and pairwise average-linkage clustering method). NFkB related genes were assessed by gene set enrichment analysis.38 We compared the 69 normal T cells and the 169 neoplastic samples for enrichment of upregulated NFkB target gene sets. The enriched gene sets were established combining the NFkB signatures from the Molecular Signatures Database,38 the Transcriptional Regulatory Element Database39 and NFkB target genes reported in large B-cell lymphoma,40 breast cancer41 and T cells.42 We randomized the data set by permuting the gene sets (10 000 times) to assess the statistical significance. Overall survival significance was assessed by log-rank test. Significance associations between categorical data were calculated by Fisher exact test.

Genome-wide DNA profiling

Fresh and/or cryopreserved primary (ALCL11 (nodal and leukemic), NE 433870L (diagnostic cervical lymph node)) and PDT lymphoma samples (ALCL11-PDT T1-1017) underwent DNA profiling using the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). Copy number variation was determined.43

Results

Discovery of a TRAF1-ALK variant chimera

Aggressive forms and rare leukemic presentation of ALK+ ALCL have been reported.3, 4, 7 To discover additional pathogenetic lesions associated to aggressive ALK+ ALCL cases, we selected a chemorefractory patient (ALCL-11) who rapidly evolved to a leukemic phase (Supplementary Figure S1A). An initial workout on the nodal ALCL lesion showed the presence of back to back lymphoma cells, displaying an intense cytoplasmic ALK positivity and a strong nuclear immunoreactivity for pSTAT3, p50 and p52 NFkB proteins (Figure 1a). These findings were consistent with a variant ALK+ translocation leading to the constitutive activation of JAK-STAT3 as well as NFkB pathways.

Figure 1
figure1

The ALCL-11 patient-derived tumorgraft line mimics its corresponding primary tissues sample. (a) Immunohistochemistry stains performed on primary diagnostic sample (ALCL-11) show a strong ALK cytoplasmic staining with an antibody (D5F3, Cell Signaling Technology) specific for an intracytoplasmic peptide of the human ALK gene ( × 400). Tissue sections stained with specific antibody against human phosphoSTAT3 (pSTAT3, x100), p50 and p52 demonstrate a variable number lymphoma cells with nuclear positivity ( × 400). These analyses were performed on the diagnostic/primary tissue sample of the ALCL-11 patient. (b) PDT engraftment and serial tumor propagation in NSG mice. Two distinct engraftments are depicted with their serial passages. Intersecting lines define the relationship among different tumors. Yellow boxes show mice the lymphoma tissue samples used for IHC stains. (c) FISH analysis was performed on the primary tissue and in a representative PDT (ALCL-11 PDT1-2152) sample using a commercial kit and break apart set recognizing the 2p23 regions (Abbott Molecular/Vysis LSI ALK Break Apart FISH Probe Kit). (d) Immunohistochemical stains were performed with specific antibodies recognizing T-cell-associated and/or -restricted antigens on the primary and serial PDT tissue samples (see Supplementary Table S1). Percentage of positive cells and intensity of staining are indicated in the above diagram. Broken patterns indicate the presence of heterogeneous staining patterns.

To establish a model representative of ALK variant ALCL, we first cultured the lymphoma cells with stromal mesenchymal elements and/or phytohaemagglutinin (PHA)-stimulated peripheral blood mononuclear cell conditioned media. This strategy was however unsuccessful (data not shown). As alternative approach, we implanted fresh leukemic cells into NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice. These resulted in the engraftment and growth of ALCL cells in all mice (100%, Figure 1b) (ALCL-11-PTD). Lymphoma grafted cells (s.c. tissue fragments or i.v. of single cells from pathological spleens) could be successfully propagated in vivo (up to 13 consecutive passages). At autopsy, mice showed a disseminated infiltration of the lymphoid organs (that is, spleen, bone marrow) and different parenchymal tissues with minor (kidneys) or extensive architectural effacements (liver) (Supplementary Figure S2). When we attempted to culture in vitro the ALCL-11 PDT cells (from passage T1 to T8, with or without stromal elements and with PHA-conditional media) no sustainable growth could be obtained (90% apoptotic cells after 96 h), suggesting that the growth of ALCL-11 PDT requires additional signals provided by the mouse-host cells.

Next, we performed a FISH to assess and correlate the ALK genomic configuration of diagnostic and PDT-derived tissues. This analysis demonstrated the presence of the genomic rearrangement of the ALK locus, in both primary and PDT cells (Figure 1c). We also applied a panel of antibodies (Supplementary Table S1) on the diagnostic biopsy and in representative tissue samples (s.c. tumor masses or spleen), derived from two independent primary engraftment lines (Figure 1b). All lymphoma cells had a similar immunophenotype (Figure 1d and Supplementary Figure S3). No differences were observed from different tissue samples (liver, spleen and so on) and/or from animals implanted at different passages and/or via alternative routes (s.c. or i.v.). Variable expression of CD2 and CD45 antigens was observed in both primary ALCL and PDT tissues, suggesting a certain degree of intraclonal diversity (Figure 1d and Supplementary Figure S3).

As ALCL-11 cells did not display any common variant fusion transcript, we used a next-generation sequencing RNAseq approach and discovered 29 reads spanning across a junction breakpoint corresponding to the TRAF1 and ALK genes. These predicted a novel chimeric TRAF1-ALK transcript encoding the first five exons of the TRAF1 gene fused in frame to the exons 20–29 of ALK (Figure 2a).21 Validation by Sanger DNA sequencing and RT-PCR confirmed the presence of TRAF1-ALK transcripts of primary, relapsed and ALCL11-PDT samples (Figure 2b). These data were then validated by additional RNAseq analyses of samples derived from additional ALCL11-PDT (data not shown).

Figure 2
figure2figure2

ALCL11 harbors the novel TRAF1-ALK fusion protein and leads to the constitutive activation of ALK signaling pathway. (a) TRAF1-ALK gene fusion was defined by RNAseq (with 29 split reads overlapping junction breakpoint across TRAF1 and ALK). The genomic coordinates are shown. TRAF1 exon 5 and ALK exon 20 reading frames were conserved (central panel). The TRAF1-ALK chimera includes the TRAF1 and Coiled-coil domains, fused to the ALK intracytoplasmic region (lower panel). (b) TRAF1-ALK fusion transcripts are detected in primary, leukemic and ALCL11-PDT samples by RT-PCR. ALK+(SUP-M2) and ALK- (MAC1) lines were used as controls. Negative controls correspond to samples lacking cDNA templates. (c) TRAF1 BA assay (see supplementary T2S) was designed to validate molecular results by FISH. Case NE 433870L showed a normal hybridization pattern of TRAF1 BA in all analyzed interphase cells. To test if the TRAF1-ALK fusion might occur by an insertion of the 3′ALK within the TRAF1 locus in case 2, we applied probes covering the 5′end of TRAF1 (SO-labeled) and the 3′end of ALK (SG-labeled) (Upper right panel). Examination with probes targeting MYC, TP53 and PRDM1 of NE 433870L diagnostic tissue showed a normal hybridization pattern for all three probes (data not shown). ALCL-11 revealed split TRAF1 BA signals in ~50% of interphase cells (Lower panel). (d) TRAF1-ALK signaling is inhibited by anti-ALK inhibitors. PDT cells (PDT-3-2330) and SUP-M2 as control were treated in vitro (6 h, Crizotinib or CEP28122, 200 nM). Total cell lysates were immune-blotted with the indicated antibodies. (e) Panel shows the normalized levels of mRNA expression of STAT3 and representative STAT3-responsive genes in untreated or (anti-ALK) CEP28122-treated ALCL-11 leukemic cells (200 nM, 6 h treatment). Expression levels were determined using a qRT-PCR approach as previously described.22, 29 Data are depicted as 2^ddCt.5. Expression levels GAPDH of untreated (reference value) and CEP28122-treated cells are reported.

To determine the frequency of TRAF1-ALK among variant ALK+ ALCL, a total of 12 archival cases with cytoplasmic ALK staining were studied by RT-qPCR or 5′-Race PCR on mRNA extracted from either formalin-fixed, paraffin-embedded or frozen tissue samples. One case, corresponding to an 11-year-old Belgian patient (NE 433870L) displayed TRAF1-ALK mRNA transcripts identical to the one detected in ALCL-11 (Supplementary Figure S4), suggesting similar breakpoints.20 ALK fusions were documented in the remaining cases using a break apart probe or RT-PCR (ATIC-ALK, TFG-ALK).44 To further characterize the TRAF1-ALK rearrangement, we designed TRAF1 break apart probes. This FISH assay revealed split signals in the interphase lymphoma cells of the diagnostic ALCL-11 sample (~50% of the total cells). Conversely, the NE 433870L sample showed a normal hybridization pattern. Thus, we applied two alternative probes covering the 5′end of TRAF1 (SO-labeled) and the 3′end of ALK (SG-labeled), demonstrating the colocalization of red/green signals (Figure 2c).

Globally, these data document the presence of genomic translocations involving the TRAF1 and the ALK loci, occurring with alternative modalities.

The TRAF1-ALK fusion leads to the constitutive activation of ALK and NFkB pathways

To define the oncogenic properties of TRAF1-ALK, we initially studied the phosphorylation status of the fusion protein and known ALK adaptors. As shown in Figure 2d, untreated ALCL-11 cells displayed a phosphorylated ALK band (~95 kDa), which was substantially reduced in samples treated with ALK inhibitors (CEP2812218 and Crizotinib). As expected, the loss of ALK signaling led also to the downregulation of pSTAT3 and pShp245 without substantial changes in cell viability and total protein expression (STAT3 and Shp2) within the first hour of treatment (6 h). Next, we evaluated the mRNA expression of genes whose expression is known to correlate with ALK-STAT3 signaling,22 demonstrating that anti-ALK treatment led to their robust downregulation (Figure 2e). Similar data were observed with NPM-ALK positive cells lines (Supplementary Figure S5a and b).

As TRAF1 interacts with TRAF2, we first demonstrated that TRAF1-ALK could bind TRAF2 (Figure 3a and b). Because the intracytoplasmic region of ALK contains a TRAF2 interacting domain,46 we constructed a truncated form of TRAF1-ALK, lacking the TRAF2 ALK docking site (ΔTRAF1-ALK or ΔT/A). Using an antibody recognizing the N-terminus of TRAF1, we demonstrated that both WT and TRAF1-ALK could co-precipitate TRAF2 (Figure 3c). Knowing that TRAF1-ALK cells express NFkB, p50 and p52 (Figure 3d), we then tested whether ΔTRAF1-ALK could elicit a NFkB-mediated transcription via a ‘bona fide’ luciferase reporter cassette in cells co-expressing CD30.46 HEK293T cells were transfected with different ALK cassettes in the presence of CD30. As previously reported,46 NPM-ALK but not ELM4-ALK downregulated the CD30-mediated NFkB activation (Figure 3e). Moreover, the forced expression of ΔTRAF1-ALK but not of ΔNPM-ALK enhanced the CD30-mediated NFkB luciferase expression (Figure 3f). To prove that the ΔTRAF1-ALK NFkB signaling requires p50 and/or p52, we co-transfected specific p50 and p52 shRNA cassettes, demonstrating decreased levels of transcription when they were coexpressed with ΔTRAF1-ALK (Figure 3f). At last, we treated ALCL-11 and/or ALCL-11 PDT cells with a proteasome inhibitor (Bortezomib) known to inhibit the NFkB signaling,47 demonstrating a dose- and time-dependent downregulation of both p50 and p52 protein levels (Figure 3g) and known NFkB-regulated genes (starting from 12 h of incubation, Figure 3h). These later changes were associated to decreased cell viability (Figure 3J) and a concomitant reduction of intracellular adenosine triphosphate content measured by relative firefly luciferase activity (PerkinElmer ATPLite, Supplementary Figure S6c). As Bortezomib can inhibit multiple targets, we tested alternative proteasome inhibitors, demonstrating similar findings in ALCL-11 or NPM-ALK cell lines (Supplementary Figure S6).

Figure 3
figure3

TRAF1-ALK leads to the constitutive activation of NFkB transcription members. (a, b) Lysates from a representative NPM-ALK cell line (SUP-M2 and Karpas 299) and leukemic ALCL-11 cells were immune-precipitated with an anti-ALK (a) and anti-TRAF1 (b) antibodies. Immuno-complexes were resolved and then blotted with the indicated antibodies. Immuno-precipitates in the presence of mouse serum are depicted as well (Beads). TL: Total Lysates, SN: Supernatant and IP Immune Precipitation. Protein molecular weights are shown. (c) Lysates from HEK293T cells, transfected with the full-length TRAF1-ALK and ΔTRAF1-ALK, were immuno-precipitated with an anti-TRAF2 antibodies. Immuno-complexes were resolved and blotted with anti-TRAF1 antibodies. The expression of the corresponding proteins prior the immune-precipitation is shown (total Lysate). Predicted protein molecular weights are indicated. (d) ALCL-11 cells show constitutive activation of the NFkB pathway. Primary ALCL-11 cells were immune-blotted with antibodies recognizing p105/p50 and p100/p52 NFkB. NPM-ALK+ ALCL cell lines were used as control. (e) Luciferase expression of transfected HEK293T cells. Cells were transfected with the indicated cassettes expressing CD30, NFkB-ROS, CD30+NPM-ALK (active form), CD30+K210R NPM-ALK (inactive form) and CD30+ EML4-ALK. (f) Knockdown of p50 or p52 impairs the NFkB-mediated luciferase expression via CD30 signaling. HEK293T cells were transfected with the indicated cassettes in the presence of a CD30 expression vector. (g) Protein expression of untreated and treated (Bortezomib 5 nM/10 nM) ALCL-11-PDTs was determined at 36 h by western blotting with specific antibodies. (h) Panel shows the normalized levels of mRNA expression of NFkB-regulated genes in untreated (control) or Bortezomib treated ALCL-11 leukemic cells (10 nM, at 6 and 12 h of culture). Expression levels were determined using a qRT-PCR approach as previously described.22, 29 Data are depicted as 2^ddCt. Expression levels GAPDH of 6 h treated (reference value) and 12 h treated cells are reported. (j) ALCL-11 cells are sensitive to Bortezomib. Primary cells (1 × 105/ml) were treated with increasing dose of the drug, overtime. Data have been normalized to control DMSO-treated cells. DMSO viability decreased over time with a 30–40% spontaneous cell death at 36 h.

Collectively, these data demonstrate that TRAF1-ALK can elicit the NFkB pathway, which contributes the TRAF1-ALK phenotype.

NFkB is activated in a subset of primary ALK positive and ALK negative ALCL

As NFkB signaling has a critical role in regulating stromal-tumor cells responses, we undertook a bioinformatics analysis to investigate whether ALCL primary samples displayed a unique NFkB signature. We first created a NFkB classifier combing established NFkB gene set lists (152 genes, Supplementary Table S3, see Material and Methods) and tested it in a large cohort of ALCL samples and normal purified T cells.29 As expected, NFkB transcripts from primary ALCL samples were significantly enriched (enrichment score=0.38, normalized enrichment score=1.78, P-value<0.001, false discovery rate<0.001) compared with purified normal, resting and activated T cells (Supplementary Figure S7a and b). The robustness of this gene set classifier was similarly validated in a cohort (GSE12195) of diffuse large B-cell lymphoma samples (Supplementary Figure S7c).48 We then demonstrated that the NFkB classifier could divide the ALCL in two different subsets (Figure 4a), which were similarly stratified using a mesenchymal signature (Figure 4b).49 Notably, these subsets displayed a strong correlation (Figure 4b and c). These findings were cross-validated with a second and independent ALCL cohort (Supplementary Figure S7d and e).36 More importantly, we proved that the ALCL subgroups, which were defined by either the stromal or NFkB signatures, displayed unique clinical outcomes and that ALK+ ALCL preferentially enriched among patients with a better outcome.

Figure 4
figure4

GSEA identifies distinct subsets of ALCL among PTCL and normal samples. (a, b) Unsupervised hierarchical clustering (NFKB and Mesenchymal1 gene set) classifies ALCL in two distinct groups, respectively, NKFBclus1/NKFBclus1, NKFBclus1/NKFBclus2 and MesClus1/MesClus2, (Pearson correlation distance measure, pairwise average-linkage clustering) with a significant association between the two groups (P-value <0.0001, Fisher exact test). (c, d) Overall survival (OS) analysis of the two molecularly defined clusters for both NFKB and mesenchymal gene set (M1=Mch1, M2=Mch2, NK1=NFKB1, NK2=NFKB2, see Supplementary figure S7) in an independent cohort of 46 ALCL. Tables show a significant correlation between the NFKB/Mesenchymal groups and the ALK status in ALCL.

At last, when we applied specific antibodies against p50 and p52 in independent set of 98 ALCL, we found that lymphoma cells (anti-p52: 20/95, 21%; anti-p50: 19/98, 19%) and non-neoplastic elements (endothelial and stromal cells) were NFkB-positive (anti-p52: 87/98, 87%; p50: 13/89, 14%, Supplementary Figure S8), suggesting that both ALCL and host cells can contribute to the NFkB signature.

The TRAF1-ALK PDT model bears high-risk genomic lesions

Although many ALK+ ALCL patients reach clinical remission, few refractory3 and rare aggressive forms, carrying translocations or copy number gains of MYC,5 have been described.5, 6, 11, 12

To identify genomic aberrations associated to TRAF1-ALK cases, we performed a copy number variation analysis. ALCL-11 leukemic and T1 and T3 PDT samples showed the heterozygous loss of 17p13 region and a concomitant missense mutation within TP53 gene exon 4 (Figure 5a). Comparison of the DNA profiles of primary, relapsed (post-therapy) and PDT tissues documented the loss of 20q (100% all samples) and a region spanning the PRDM1/Blimp1 gene (6q, 30% PDTs). Interestingly, PDT samples displayed amplification at 8q (42% of all cells), a region containing the MYC gene, a finding further confirmed by FISH (Supplementary Table S4) and by a strong nuclear expression of MYC (>90%) (Figure 5b). On the contrary, the NE 433870L TRAF1-ALK ALCL sample showed minor copy number variation changes and a normal genomic configuration of MYC, PRDM1/Blimp1 and TP53 genes. This later patient had a remarkable response to chemotherapy and remained in clinical remission (Supplementary Figure 1S), suggesting that the acquisition multiple genetic defects may predict for clinical outcomes.

Figure 5
figure5

CGH analysis of primary and PDT ALCL-11 show the emergency of subclonal population lacking TP53 and MYC amplification. (a) SNP-array plots of ALCL11-PDT identified a los at 17p13.1 (TP53) and 6q21 (PRDM1) and a gene amplification at 8q24 (MYC). X axis: chromosome localization and physical mapping; Y axis: signal indicating copy number status at each locus. DNA sequencing of normal and pathological DNA derived form Patient ALCL-11. (b) IHC stains of primary and PDTs (ALCL-11-PDT-T4) tissue samples by an anti-MYC (Y69, Epitomics, Burlingame, CA) and Ki-67 (MIB-1, Dako Italia S.p.A, Italy) Mab. Original magnification × 400.

ALK inhibition can improve the outcome of ALCL-11 PDT mice

As the management of chemorefractory ALCL patients remains problematic, we tested the therapeutic efficacy of a selected ALK inhibitor in our ALCL-11 PDT model. Mice were i.v. tail injected with tumor cells (1 × 106). Engraftment and disease evolution were assessed by enumerating circulating CD30+ cells and by total body magnetic resonance imaging. As a therapeutic scheme, we selected a 14- or 21-day protocol (CEP28122 100 mg/kg/BID), proven to eradicate disease in NPM-ALK PDT model obtained from a CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemorefractory ALCL patient.18 As shown in Figure 6a and b, untreated mice had an increasing number of circulating CD30 cells and enlarging spleens (Supplementary Figure S9) and 62% them succumbed at day 28 (90% after 37 from injection). In contrast, 88% of mice treated for 7 days (21 days from injection+7 days treatment) were alive at day 28. Disease progression was controlled in mice treated for 14 consecutive days (Figure 6c). With a longer treatment (21 days), both spleen size and the percentage of circulating CD30 cells decreased, with an improvement of the over survival (P<0.0001). Nevertheless, when the inhibitor was withdrawn, circulating lymphoma cells and spleen sizes rose again (Figure 6a and b and Supplementary Figure S10) and mice eventually succumbed with disease (90% at day 60).

Figure 6
figure6

Single therapy with anti-ALK inhibitor leads to a partial response of ALCL1-11-PDT mice. (a) ALCL-11 PDT2-6 (injected with 1x106 lymphoma cells, i.v) were analyzed using a dedicated MRI unit to determine the volume of the spleen as a surrogate of lymphoma/leukemia burden. Mice were treated with CEP28122, 100 mg/kg/BID starting day 21th from the i.v. inoculum and scanned a different intervals (7, 14 or 21 days). A cohort of treated mice (14 days) were then released and followed over time (7 or 14 days off). Numbers of mice are indicated. (b) ALCL-11 PDT2-6 (injected with 1 × 106 lymphoma cells, i.v) were bled and blood-circulating human CD45+CD30+ cells were determined by flow cytometry. Mice were treated with CEP28122, 100 mg/kg/BID as indicated above. Numbers of mice are indicated. (c) Effect of CEP28122 treatment in ALCL-11 PDT. Columns plot of mice injected with 1x106 ALCL-11 cells (i.v. day 21, gray bars) and CEP28122 response (day 21+14, back bars) after 2 weeks of treatment, compared with tumor volume at baseline (day 21), in 24 cases. (d) Overall survival of ALCL-11-PDT treated with anti-ALK (CEP28122). Mice were randomized and treated as indicated with 100 mg/kg/BID CEP28122 as indicated.

These data demonstrate that ALK+ chemorefractory leukemic forms can be susceptible to anti-ALK kinase inhibitors, remaining addicted to ALK signaling.

Discussion

We have provided evidence of the pathogenetic role of a novel TRAF1-ALK translocation and potential utility of anti-ALK inhibitors in aggressive leukemic forms of ALK+ ALCL. The TRAF1-ALK fusion chimera leads to the concomitant activation of ALK and NFkB pathways, which contribute to the maintenance of the neoplastic phenotype. Moreover, NFkB as well as mesenchymal gene set classifiers can stratify ALCL patients and predict clinical outcomes.

It is well established that ALK fusions are powerful oncogenes8, 50 leading to the constitutive activation of JAK/STAT, PI3K/AKT, Ras/ERK1-2 and PLC-γ pathways.8, 45 Moreover, ALK chimera can interact with TRAF2 and modulate the CD30-mediated activation of NFkB.46 However, the contribution of NFkB signaling in ALCL tumorigenesis remains controversial. ALK+ ALCL cell lines have been reported to be devoid of p50 nuclear-binding activity.51, 52 On the contrary, Bcl-3 and p52 are seen in primary ALCL53 and micro-dissected ALCL lymphoma cells preferentially express NFkB target genes.54 Our data have confirmed these findings and demonstrated that a gene data set classifier of NFkB can reproducibly stratify ALCL, irrespectively of their ALK status. Interestingly, when we applied a mesenchymal gene set, known to stratify diffuse large B-cell lymphoma and to predict clinical outcome, ALCL were also clustered in two major subgroups, which strongly correlated with those defined by the NFkB signature. These data suggest that NFkB signaling may dictate specific responses in lymphoma as well as in host cells. The fact that ALCL subgroups have unique clinical outcomes is relevant and may provide a novel tool to define poor responders with ALK+ ALCL.

Indeed, the pharmacological inhibition of the proteasome degradation known to modulate the NFkB pathway could represent a novel therapeutic modality. NFkB inhibitors could target either the lymphoma cells (TRAF1-ALK) or the host elements with a modality previously reported in other settings.55, 56 Targeting the microenvironment has been recently proposed as analogous strategy in ALCL patients.57

As many ALK and a sizable subset of ALK+ALCL (20–30%) fail to reach clinical remission and prolong disease-free survival,3, 11 predicting that biomarkers are highly desirable. The loss of TP53, PRDM1/Blimp110 and TP6358 and deregulated expression of MYC 5 might pinpoint, at diagnosis, refractoriness/relapse or even aggressive forms of ALCL. In our PDT model, the emergency of subclones carrying defects of PRDM1/Blimp1 and MYC supports the hypothesis that these lesions may have a relevant pathogenetic role and might occur as additional event along tumorigenesis contributing to more aggressive phenotype. A scenario previously described in acute lymphoblastic/leukemic PDT models.59

We have described the properties of a novel TRAF1-ALK fusion showing the unique contribution of its N-terminal TRAF1 region and demonstrated how ALK and NFkB can contribute to the neoplastic phenotype. The generation of PDT should represent a powerful approach to design more efficacious therapies in individual patients, particularly in the setting of relapses or refractoriness.

References

  1. 1

    Falini B, Martelli MP . Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica 2009; 94: 897–900.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2

    Swerdlow SH CE, Haris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW . WHO classification of tumors of haemotolopoietic and lymphoid tissues, 4th edn. Stylus Publishing, LLC: Sterling VA, 2008.

    Google Scholar 

  3. 3

    Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496–5504.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4

    Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418–3425.

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Monaco S, Tsao L, Murty VV, Nandula SV, Donovan V, Oesterheld J et al. Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase. Am J Hematol 2007; 82: 59–64.

    Article  PubMed  Google Scholar 

  6. 6

    Liang X, Branchford B, Greffe B, McGavran L, Carstens B, Meltesen L et al. Dual ALK and MYC Rearrangements Leading to an Aggressive Variant of Anaplastic Large Cell Lymphoma. J Pediatr Oncol 2013; 35: e209–e213.

    Article  Google Scholar 

  7. 7

    Ferreri AJ, Govi S, Pileri SA, Savage KJ . Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncology Hematol 2012; 83: 293–302.

    Article  Google Scholar 

  8. 8

    Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011; 47: R11–R23.

    CAS  Article  PubMed  Google Scholar 

  9. 9

    Miranda C, Roccato E, Raho G, Pagliardini S, Pierotti MA, Greco A . The TFG protein, involved in oncogenic rearrangements, interacts with TANK and NEMO, two proteins involved in the NF-kappaB pathway. J Cell Physiol 2006; 208: 154–160.

    CAS  Article  PubMed  Google Scholar 

  10. 10

    Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo F et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood 2013; 122: 2683–2693.

    CAS  Article  PubMed  Google Scholar 

  11. 11

    Grewal JS, Smith LB, Winegarden JD 3rd, Krauss JC, Tworek JA, Schnitzer B . Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature. Ann Hematol 2007; 86: 499–508.

    Article  PubMed  Google Scholar 

  12. 12

    Moritake H, Shimonodan H, Marutsuka K, Kamimura S, Kojima H, Nunoi H . C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC. Am J Hematol 2011; 86: 75–78.

    CAS  Article  PubMed  Google Scholar 

  13. 13

    Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012; 12: 786–798.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14

    Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ . Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593–598.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15

    Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9: 338–350.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16

    Garber K . From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009; 101: 6–8.

    Article  PubMed  Google Scholar 

  17. 17

    Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 2012; 26: 1517–1526.

    CAS  Article  PubMed  Google Scholar 

  18. 18

    Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 2011; 11: 670–679.

    Article  PubMed  Google Scholar 

  19. 19

    Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C et al. An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Res 2006; 12: 4652–4661.

    CAS  Article  Google Scholar 

  20. 20

    Feldman AL, Vasmatzis G, Asmann YW, Davila J, Middha S, Eckloff BW et al. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. Genes Chromosomes Cancer 2013; 52: 1097–1102.

    CAS  Article  PubMed  Google Scholar 

  21. 21

    Tabbo F, Barreca A, Machiorlatti R, Messana K, Landra I, Abate F et al. Humanized NOD/Scid/IL2g−/− tumor grafts recapitulate primary anaplastic large cell lymphoma. AACR Annual Meeting 2013 2013; (abstract 3853).

  22. 22

    Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 2010; 28: 1583–1590.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23

    Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46: 166–170.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24

    Abate F, Acquaviva A, Paciello G, Foti C, Ficarra E, Ferrarini A et al. Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model. Bioinformatics 2012; 28: 2114–2121.

    CAS  Article  PubMed  Google Scholar 

  25. 25

    McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011; 7: e1001138.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26

    Iyer MK, Chinnaiyan AM, Maher C . ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011; 27: 2903–2904.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27

    Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231–1235.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. 28

    Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000; 95: 2144–2149.

    CAS  PubMed  Google Scholar 

  29. 29

    Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 2012; 120: 1274–1281.

    CAS  Article  PubMed  Google Scholar 

  30. 30

    Shultz LD, Ishikawa F, Greiner DL . Humanized mice in translational biomedical research. Nat Rev Immunology 2007; 7: 118–130.

    CAS  Article  PubMed  Google Scholar 

  31. 31

    Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 2013; 98: 953–963.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. 32

    Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038–1047.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33

    Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006; 107: 689–697.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34

    Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L et al. The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood 2009; 113: 2776–2790.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. 35

    Fu L, Medico E . FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data. BMC Bioinformatics 2007; 8: 3.

    Article  PubMed  PubMed Central  Google Scholar 

  36. 36

    Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123: 2915–2923.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37

    Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP . GenePattern 2.0. Nat Genet 2006; 38: 500–501.

    CAS  Article  Google Scholar 

  38. 38

    Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Nat l Acad Sci USA 2005; 102: 15545–15550.

    CAS  Article  Google Scholar 

  39. 39

    Jiang C, Xuan Z, Zhao F, Zhang MQ . TRED: a transcriptional regulatory element database, new entries and other development. Nucleic Acids Res 2007; 35: D137–D140.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40

    Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392–1399.

    CAS  Article  PubMed  Google Scholar 

  41. 41

    Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK et al. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol Cell 2011; 43: 798–810.

    CAS  Article  Google Scholar 

  42. 42

    Nagar M, Jacob-Hirsch J, Vernitsky H, Berkun Y, Ben-Horin S, Amariglio N et al. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol 2010; 184: 3570–3581.

    CAS  Article  PubMed  Google Scholar 

  43. 43

    Rinaldi A, Kwee I, Young KH, Zucca E, Gaidano G, Forconi F et al. Genome-wide high resolution DNA profiling of hairy cell leukaemia. Br J Haematol 2013; 162: 566–569.

    CAS  Article  PubMed  Google Scholar 

  44. 44

    Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002; 34: 354–362.

    CAS  Article  PubMed  Google Scholar 

  45. 45

    Tabbo F, Barreca A, Piva R, Inghirami G . ALK signaling and target therapy in anaplastic large cell lymphoma. Front Oncol 2012; 2: 41.

    Article  PubMed  PubMed Central  Google Scholar 

  46. 46

    Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell 2004; 5: 353–364.

    CAS  Article  PubMed  Google Scholar 

  47. 47

    Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046–1052.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  48. 48

    Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717–721.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49

    Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Eng J Med 2008; 359: 2313–2323.

    CAS  Article  Google Scholar 

  50. 50

    Zhang Q, Wei F, Wang HY, Liu X, Roy D, Xiong QB et al. The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. Am J Pathol 2013; 183: 1971–1980.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. 51

    Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19: 2254–2263.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  52. 52

    Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340–4347.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. 53

    Mathas S, Johrens K, Joos S, Lietz A, Hummel F, Janz M et al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005; 106: 4287–4293.

    CAS  Article  PubMed  Google Scholar 

  54. 54

    Eckerle S, Brune V, Doring C, Tiacci E, Bohle V, Sundstrom C et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009; 23: 2129–2138.

    CAS  Article  PubMed  Google Scholar 

  55. 55

    Hiruma Y, Honjo T, Jelinek DF, Windle JJ, Shin J, Roodman GD et al. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 2009; 113: 4894–4902.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  56. 56

    Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 2007; 21: 1521–1531.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57

    Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med 2012; 18: 1699–1704.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  58. 58

    Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012; 120: 2280–2289.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59

    Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011; 208: 653–661.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

GI is supported by the Italian Association for Cancer Research Special Program in Clinical Molecular Oncology, Milan (5 × 1000 No. 10007); Regione Piemonte (ONCOPROT, CIPE 25/2005); ImmOnc (Innovative approaches to boost the immune responses, Programma Operativo Regionale, Piattaforme Innovative BIO FESR 2007/13, Asse 1 ‘Ricerca e innovazione’ della LR 34/2004) and the Oncology Program of Compagnia di San Paolo, Torino. SP and BF are supported by the Italian Association for Cancer Research Special Program in Clinical Molecular Oncology, Milan (5x1000 No. 10007); RR by Partnership for Cure, NIH 1 P50 MH094267-01, NIH 1 U54 CA121852-05, NIH 1R01CA164152-01. FB is sponsored by the Oncosuisse KLS-02403-02-2009 (Bern, Switzerland); Anna Lisa Stiftung (Ascona, Switzerland); Nelia and Amadeo Barletta Foundation (Lausanne, Switzerland); RP by Rete Oncologica del Piemonte e della Valle d’Aosta. LDS is sponsored by National Institutes of Health (USA) grant CA034196. MB, MT, IL, FT FDG, RC and LB are enrolled in the PhD program (Pharmaceutical Sciences, University of Geneva, Switzerland and Molecular Medicine, University of Torino, respectively). We thank Drs Vigliani C, Fioravanti A and Mossino M for their technical support and Dr Casano J for the constructive revision of the manuscript.

Author information

Affiliations

Authors

Consortia

Corresponding authors

Correspondence to R Rabadan or F Bertoni or G Inghirami.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Appendix

Appendix

Appendix The European T-Cell Lymphoma Study Group:

Italy: Cristina Abele, Luca Bessone, Antonella Barreca, Michela Boi, Federica Cavallo, Nicoletta Chiesa, Ramona Crescenzo, Antonella Fienga, Marcello Gaudiano, Filomena di Giacomo, Giorgio Inghirami, Indira Landra, Elena Lasorsa, Rodolfo Marchiorlatti, Barbara Martinoglio, Enzo Medico, Gian Battista Ferrero, Katia Messana, Elisabetta Mereu, Elisa Pellegrino, Roberto Piva, Irene Scafò, Elisa Spaccarotella, Fabrizio Tabbò, Maria Todaro, Ivana Ubezzi, Susanna Urigu (Azienda Ospedaliera Città della Salute e della Scienza di Torino, University of and Center for Experimental Research and Medical Studies); Domenico Novero, Annalisa Chiapella and Umberto Vitolo (Azienda Ospedaliera Città della Salute e della Scienza di Torino and San Luigi Gonzaga, Turin); Francesco Abate, Elisa Ficarra, Andrea Acquaviva (Politecnico di Torino); Luca Agnelli and Antonino Neri (University of Milan); Anna Caliò Marco Chilosi and Alberto Zamó (University of Verona); Fabio Facchetti and Silvia Lonardi (University of Brescia); Anna De Chiara and Franco Fulciniti (National Cancer Institute, Naples); Andrés Ferreri and Maurilio Ponzoni (San Raffaele Institute, Milan); Claudio Agostinelli, Pier Paolo Piccaluga and Stefano Pileri (University of Bologna); Brunangelo Falini and Enrico Tiacci (University of Perugia). Belgium: Peter Van Loo, Thomas Tousseyn, and Christiane De Wolf-Peeters (University of Leuven); Germany: Eva Geissinger, Hans Konrad Muller-Hermelink and Andreas Rosenwald, (University of Wuerzburg); Spain: Miguel Angel Piris and Maria E. Rodriguez (Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander and Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM, Madrid); Switzerland: Francesco Bertoni, Andrea Rinaldi, Ivo Kwee (Institute of Oncology Research, Bellizona). Brasil: Carlos Chiattone (Disciplina de Hematologia e Oncologia, FCM da Santa Casa de São Paulo) and Roberto Antonio Pinto Paes (Department of Pathology FCM da Santa Casa de São Paulo).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abate, F., Todaro, M., van der Krogt, JA. et al. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia 29, 1390–1401 (2015). https://doi.org/10.1038/leu.2014.347

Download citation

Further reading

Search

Quick links